You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms
SBC: THERATARGET, INC. Topic: 106NARRATIVE This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymerSELPsilk elastinlike proteinKto embolize cerebral aneurysmsThe SELP embolic would reduce the risk of aneurysm rupture while minimizing the risk of recanalization after treatment and providing a platform for del ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Automated Electrophysiology Assessment of Drug induced Cardiotoxicity Based on Parallel Noninvasive Nanoelectrode Array
SBC: CYION TECHNOLOGIES LLC Topic: NIBIBSummary Drug safety issues pose a serious challenge to the health and well being of patients The development of our innovative technology aims to address a significant gap in the in vitro assessment of drug induced cardiotoxicity which is the number one reason for withdrawals of all marketed drugs as well as the premature termination of promising drug development candidates Pressured by the eno ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Skin Microbiome Editing with Fermentation Initiator
SBC: Surface Bioadvances, Inc. Topic: NIAMSAbstract Acne dysbiosis is defined as microbial imbalance with the over growth of Propionibacterium acnes P acnes in the acne microbiome We have demonstrated that Staphylococcus epidermidis S epidermidis a probiotic bacterium co existed with P acnes in an acne lesion can exploit the carbohydrate fermentation to produce short chain fatty acids SCFAs and rein in the over growth of P ac ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma
SBC: InhiProt Topic: 103Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Treatment for Traumatic Brain Injury
SBC: Epigen Biosciences, Inc. Topic: 101SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of Pirenzepine for HIV SN
SBC: WinSanTor, Inc. Topic: 101PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome
SBC: CELDARA MEDICAL, LLC Topic: RProject Summary Rodent borne viral outbreaks are increasing in both frequency and impactAs weather patterns evolverodent populations are affected and may multiply in areas where increased contact with humans results in infectionHantavirusesincluding AndesANDVand Sin NombreSNVare transmitted through the excreta of infected rodents andwhen aerosolizedinfect humansIn the Americashantavirus infection ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel therapy for Fragile X syndrome
SBC: Epigen Biosciences, Inc. Topic: 101PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Unified System for Wireless Optogenetics and Brain Microdialysis for Small Molecules Prototype Development and Validation
SBC: AMUZA, INC Topic: 101PROJECT SUMMARY While optogenetics is well suited for understanding the dynamic activity of neural circuits the first central theme of the NIH BRAIN Initiative PAR its neurochemical impacts remain largely uncharacterized due to a lack of appropriate tools Given that the predominant mode of cellular interactions is neurochemical commercial development of such tools will fulfill the ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
SA FasL engineered human islets as a novel product for the treatment of type diabetes
SBC: FasCure Therapeutics LLC Topic: NIDDKPROJECT SUMMARY Type diabetes T D is a chronic autoimmune disorder that affects of population worldwide Exogenous insulin treatment is the standard of care for T D but often negatively affects the quality of life and is ineffective in preventing recurrent hyperglycemia episodes and chronic complications Recent studies show that human islet allografts can restore long term normoglycemia ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health